Altimmune (NASDAQ:ALT) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

A number of other research analysts have also recently commented on the company. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.71.

Altimmune Stock Up 1.6 %

ALT stock opened at $6.94 on Wednesday. The company’s 50-day moving average price is $7.92 and its two-hundred day moving average price is $7.20. Altimmune has a 12 month low of $5.28 and a 12 month high of $14.84. The firm has a market cap of $493.57 million, a P/E ratio of -4.48 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Equities analysts predict that Altimmune will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC bought a new stake in Altimmune in the third quarter valued at approximately $31,000. 180 Wealth Advisors LLC bought a new stake in Altimmune during the fourth quarter valued at $78,000. XTX Topco Ltd acquired a new stake in Altimmune during the 2nd quarter worth about $96,000. PFG Investments LLC bought a new position in shares of Altimmune in the 4th quarter worth about $96,000. Finally, Stifel Financial Corp boosted its position in shares of Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.